191 related articles for article (PubMed ID: 21327054)
41. Combination stroke therapy in the mouse with blood-brain barrier penetrating IgG-GDNF and IgG-TNF decoy receptor fusion proteins.
Sumbria RK; Boado RJ; Pardridge WM
Brain Res; 2013 Apr; 1507():91-6. PubMed ID: 23428543
[TBL] [Abstract][Full Text] [Related]
42. Monoclonal antibody-glial-derived neurotrophic factor fusion protein penetrates the blood-brain barrier in the mouse.
Zhou QH; Boado RJ; Lu JZ; Hui EK; Pardridge WM
Drug Metab Dispos; 2010 Apr; 38(4):566-72. PubMed ID: 20075191
[TBL] [Abstract][Full Text] [Related]
43. Pharmacokinetics and safety in rhesus monkeys of a monoclonal antibody-GDNF fusion protein for targeted blood-brain barrier delivery.
Pardridge WM; Boado RJ
Pharm Res; 2009 Oct; 26(10):2227-36. PubMed ID: 19609743
[TBL] [Abstract][Full Text] [Related]
44. Design and characterization of a novel dimeric blood-brain barrier penetrating TNFα inhibitor.
Manrique-Suárez V; Macaya L; Contreras MA; Parra N; Maura R; González A; Toledo JR; Sánchez O
Proteins; 2021 Nov; 89(11):1508-1521. PubMed ID: 34219271
[TBL] [Abstract][Full Text] [Related]
45. Genetic engineering, expression, and activity of a chimeric monoclonal antibody-avidin fusion protein for receptor-mediated delivery of biotinylated drugs in humans.
Boado RJ; Zhang Y; Zhang Y; Xia CF; Wang Y; Pardridge WM
Bioconjug Chem; 2008 Mar; 19(3):731-9. PubMed ID: 18278853
[TBL] [Abstract][Full Text] [Related]
46. TNFalpha transport across the blood-brain barrier is abolished in receptor knockout mice.
Pan W; Kastin AJ
Exp Neurol; 2002 Apr; 174(2):193-200. PubMed ID: 11922661
[TBL] [Abstract][Full Text] [Related]
47. Plasma Pharmacokinetics of Valanafusp Alpha, a Human Insulin Receptor Antibody-Iduronidase Fusion Protein, in Patients with Mucopolysaccharidosis Type I.
Pardridge WM; Boado RJ; Giugliani R; Schmidt M
BioDrugs; 2018 Apr; 32(2):169-176. PubMed ID: 29442294
[TBL] [Abstract][Full Text] [Related]
48. IgG Fusion Proteins for Brain Delivery of Biologics via Blood-Brain Barrier Receptor-Mediated Transport.
Boado RJ
Pharmaceutics; 2022 Jul; 14(7):. PubMed ID: 35890374
[TBL] [Abstract][Full Text] [Related]
49. Bi-functional IgG-lysosomal enzyme fusion proteins for brain drug delivery.
Boado RJ; Lu JZ; Hui EK; Lin H; Pardridge WM
Sci Rep; 2019 Dec; 9(1):18632. PubMed ID: 31819150
[TBL] [Abstract][Full Text] [Related]
50. IgG-enzyme fusion protein: pharmacokinetics and anti-drug antibody response in rhesus monkeys.
Boado RJ; Hui EK; Lu JZ; Pardridge WM
Bioconjug Chem; 2013 Jan; 24(1):97-104. PubMed ID: 23249376
[TBL] [Abstract][Full Text] [Related]
51. A monoclonal antibody-GDNF fusion protein is not neuroprotective and is associated with proliferative pancreatic lesions in parkinsonian monkeys.
Ohshima-Hosoyama S; Simmons HA; Goecks N; Joers V; Swanson CR; Bondarenko V; Velotta R; Brunner K; Wood LD; Hruban RH; Emborg ME
PLoS One; 2012; 7(6):e39036. PubMed ID: 22745701
[TBL] [Abstract][Full Text] [Related]
52. Biopharmaceutical drug targeting to the brain.
Pardridge WM
J Drug Target; 2010 Apr; 18(3):157-67. PubMed ID: 20064077
[TBL] [Abstract][Full Text] [Related]
53. Evolving new-age strategies to transport therapeutics across the blood-brain-barrier.
Choudhari M; Hejmady S; Narayan Saha R; Damle S; Singhvi G; Alexander A; Kesharwani P; Kumar Dubey S
Int J Pharm; 2021 Apr; 599():120351. PubMed ID: 33545286
[TBL] [Abstract][Full Text] [Related]
54. Blood-Brain Barrier Transport, Plasma Pharmacokinetics, and Neuropathology Following Chronic Treatment of the Rhesus Monkey with a Brain Penetrating Humanized Monoclonal Antibody Against the Human Transferrin Receptor.
Pardridge WM; Boado RJ; Patrick DJ; Ka-Wai Hui E; Lu JZ
Mol Pharm; 2018 Nov; 15(11):5207-5216. PubMed ID: 30226787
[TBL] [Abstract][Full Text] [Related]
55. Structural basis for tumor necrosis factor blockade with the therapeutic antibody golimumab.
Ono M; Horita S; Sato Y; Nomura Y; Iwata S; Nomura N
Protein Sci; 2018 Jun; 27(6):1038-1046. PubMed ID: 29575262
[TBL] [Abstract][Full Text] [Related]
56. Re-engineering therapeutic antibodies for Alzheimer's disease as blood-brain barrier penetrating bi-specific antibodies.
Pardridge WM
Expert Opin Biol Ther; 2016 Dec; 16(12):1455-1468. PubMed ID: 27572805
[TBL] [Abstract][Full Text] [Related]
57. Drug targeting to the brain.
Pardridge WM
Pharm Res; 2007 Sep; 24(9):1733-44. PubMed ID: 17554607
[TBL] [Abstract][Full Text] [Related]
58. Targeted delivery of protein and gene medicines through the blood-brain barrier.
Pardridge WM
Clin Pharmacol Ther; 2015 Apr; 97(4):347-61. PubMed ID: 25669455
[TBL] [Abstract][Full Text] [Related]
59. Reduction in Brain Heparan Sulfate with Systemic Administration of an IgG Trojan Horse-Sulfamidase Fusion Protein in the Mucopolysaccharidosis Type IIIA Mouse.
Boado RJ; Lu JZ; Hui EK; Pardridge WM
Mol Pharm; 2018 Feb; 15(2):602-608. PubMed ID: 29251941
[TBL] [Abstract][Full Text] [Related]
60. Re-engineering erythropoietin as an IgG fusion protein that penetrates the blood-brain barrier in the mouse.
Zhou QH; Boado RJ; Lu JZ; Hui EK; Pardridge WM
Mol Pharm; 2010 Dec; 7(6):2148-55. PubMed ID: 20860349
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
